Time spent for activation of non-profit studies in oncology in Italy

PLoS ONE

Volumn 5, Issue 7, 2010, Pages

  de Feo, Gianfranco ^a   Signoriello, Simona ^b   Bryce, Jane C ^a   del Giudice, Antonia ^a   Canzanella, Giuliana ^a   Crudele, Federika ^a   Romano, Fiorella ^a   de Matteis, Giovanni ^a   Florio, Manuela ^a   Falasconi, Fabiano ^a   Savio, Alfonso ^a   Giordano, Pasqualina ^a   Daniele, Gennaro ^a   Iaccarino, Mario ^a   Piccirillo, Maria Carmela ^a   di Maio, Massimo ^a   Morabito, Alessandro ^a   Gallo, Ciro ^b   Perrone, Francesco ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER RESEARCH; CLINICAL STUDY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DESCRIPTIVE RESEARCH; EUROPE; ITALY; NATIONAL HEALTH ORGANIZATION; NON PROFIT ORGANIZATION; ONCOLOGY; PRACTICE GUIDELINE; PROFESSIONAL STANDARD; QUALITY CONTROL; TREND STUDY; CLINICAL TRIAL; HUMAN; MULTICENTER STUDY; STATISTICS;

CLINICAL TRIALS AS TOPIC; GUIDELINES AS TOPIC; HUMANS; ITALY; MULTICENTER STUDIES AS TOPIC; ORGANIZATIONS, NONPROFIT;

EID: 77955626801     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0011864     Document Type: Article

References (14)

1. European Parliament (2001) Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Official Journal of the European Communities 1-52001, L 121/34-44.
2. Ministero della Salute della Repubblica Italiana (2003) Decreto Legislativo 24 Giugno 2003 n. 211: Attuazione della Direttiva 2001/20/C relativa all'appli-cazione della buona pratica clinica nell'esecuzione delle sperimentazioni cliniche di medicinali per uso clinico. Supplemento ordinario alla Gazzetta Ufficiale n.184 del 9/8/2003.
3. Ministero della Salute della Repubblica Italiana (2004) Decreto Ministeriale 17 Dicembre 2004: Prescrizioni e condizioni di carattere generale, relative all'esecuzione delle sperimentazioni cliniche dei medicinali, con particolare riferimento a quelle ai fini del miglioramento della pratica clinica, quale parte integrante dell'assistenza sanitaria. Gazzetta Ufficiale n. 43 del 22/2/2005.
4. Italian Medicines Agency (2008) Seventh Bulletin of clinical trials of drugs in Italy. Available: http://oss-sper-clin.agenziafarmaco.it.
5. Porcu L, Poli D, Torri V, Rulli E, Di Tullio MC, et al. (2008) Impact of recent legislative bills regarding clinical research on Italian ethics committee activity. J Med Ethics 34: 747-750.
6. European Parliament (2005) Detailed guidance for the request for authorisation of a clinical trial on a medicinal product for human use to the competent authorities, notification ofsubstantial amendments and declaration of the end of the trial. Available: http://ec.europa.eu/enterprise/sectors/pharmaceuticals/files/eudralex/vol-10/11_ca_14-2005_en.pdf.
7. European Parliament (2006) Detailed guidance on the application format and documentation to be submitted in an application for an Ethics Committee opinion on the clinical trial on medicinal products for human use. Available: http://ec.europa.eu/enterprise/sectors/pharmaceuticals/files/eudralex/vol-10/12_ec_guideline_20060216_en.pdf.
8. European Parliament (2007) Guidance on Investigational Medicinal Products (IMPs) and other medicinal products used in Clinical Trials. Available: http://ec.europa.eu/enterprise/sectors/pharmaceuticals/files/eudralex/vol-10/guidance-on-imp_nimp_04-2007_en.pdf.
9. Ministero della Salute della Repubblica Italiana (2007) Decreto Ministeriale 21 Dicembre 2007: Modalitá di inoltro della richiesta di autorizzazione alTAutorita competente, per la comunicazione di emendamenti sostanziali e la dichiarazione di conclusione della sperimentazione clinica e per la richiesta di parere al comitato etico. Supplemento ordinario alla Gazzetta Ufficiale n. 53 del 3/3/2008.
10. Eigth Bulletin of clinical trials of drugs in Italy (2009) Available: http://oss-sper-clin.agenziafarmaco.it.
11. Dilts DM, Sandler AB (2006) Invisible barriers to clinical trials: The impact of structural, infrastructural, and procedural barriers to opening oncology clinical trials. J Clin Oncol 24: 4545-4552.
12. Dilts DM, Sandler AB, Cheng SK, Crites JS, Ferranti LB, et al. (2009) Steps and Time to Process Clinical Trials at the Cancer Therapy Evaluation Program. J Clin Oncol 27: 1761-1766.
13. Duley L, Antman K, Arena J, Avezum A, Blumenthal M, et al. (2008) Specific barriers to the conduct of randomised trials. Clinical Trials 5: 40-48.
14. Stewart DJ, Whitney SN, Kurzrock R (2010) Equipoise Lost: Ethics, Costs, and the Regulation ofCancer Clinical Research. J Clin Oncol, Available: http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2009.27.5404.